GLP-1 is a natural human hormone that regulates blood glucose levels. Scientists have now created long-lasting GLP-1 drugs ...
GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...
SAN DIEGO — Patients with obesity and diabetes are at a substantially reduced risk of having a recurrence of atrial fibrillation (AF) after ablation if they are taking a glucagon-like peptide 1 (GLP-1 ...
GLP-1 receptor agonists may reduce the risk of obesity-related cancers in patients with type 2 diabetes by 7% compared to DPP-4 inhibitors. The study involved 170,030 adults with T2D and obesity, ...
People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems.
Everyday Health on MSN
Can GLP-1 Drugs for Obesity and Diabetes Also Treat Other Diseases?
Researchers are exploring drugs like Ozempic, Mounjaro, and Wegovy to treat or prevent a range of conditions, including ...
Discover a study comparing tirzepatide, semaglutide, and liraglutide in MASLD, revealing significant reductions in liver ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonists reduced mortality vs. DDP-4 ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...
Although the use of glucagon-like peptide 1 (GLP-1) receptor agonists and other antidiabetic medications continues to increase among pregnant women with type 2 diabetes, current evidence suggests no ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback